SUPN

MKT CAP:$3B

Supernus Pharmaceuticals Inc

Market Cap

$3B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$44.48-$4.99 (-10.09%)

Jun 8, 2026

52W High $57.0052W Low $31.16

Company Details

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant in...

CEO

—

IPO Date

May 1, 2012

Website

www.supernus.com

Key Metrics TTM

Revenue

$777M

+16.3% YoY

Net Income

-$29M

EPS (Diluted)

Free Cash Flow

$82M

Revenue / Share

$13.48

Gross Margin

89.4%

Operating Margin

-5.4%

Net Margin

-3.7%

FCF Margin

10.6%

P/S

3.3x

P/E

Earnings Reports

Q2 2026

Aug 4, 2026

PENDING

Q1 2026

May 5, 2026

$208M+38.6%

FY 2025

Mar 2, 2026

$719M+8.6%

Q4 2025

Mar 2, 2026

$212M+21.5%

Q3 2025

Nov 6, 2025

$192M+9.3%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee